Trial Profile
An observational, multinational, multi-center, prospective, open-label study to asses effectiveness, safety and tolerability of treatment with vildagliptin or vildagliptin plus metformin (SPC) in type 2 diabetes mellitus patients in a real-world setting - GUARD
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 05 Mar 2018
Price :
$35
*
At a glance
- Drugs Vildagliptin (Primary) ; Vildagliptin/metformin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms GUARD
- Sponsors Novartis Healthcare
- 01 May 2017 Results (n=2786) assessing the effectiveness, safety, and tolerability of vildagliptin treatment with or without metformin in the patient subset from Egypt, published in the Current Medical Research and Opinion.
- 30 Dec 2010 New trial record